CHRNA3

CHRNA3 encodes the α3 subunit of neuronal nicotinic acetylcholine receptors (nAChRs), which is essential for fast cholinergic synaptic transmission in autonomic ganglia and contributes to central nervous system circuits underlying sensorimotor gating, locomotion, and alcohol-related behaviors. Mice lacking the α3 subunit exhibit megacystis, pupil dilation, growth failure, and perinatal lethality due to loss of ganglionic nicotinic transmission (PMID:11450844), and biallelic loss-of-function variants in humans cause familial panautonomic failure with neurogenic orthostatic hypotension, gastrointestinal dysmotility, and bladder dysfunction (PMID:33947782, PMID:38192228). CHRNA3 transcription is regulated by a cis-acting enhancer containing rs2036527 that is bound by FOXA2 and physically loops to the CHRNA3 promoter, with additional allele-specific regulatory inputs from intergenic SNPs (rs8023462, rs6495309) that recruit GATA factors and modulate expression in a cell-type-dependent manner (PMID:40755048, PMID:23872218). In the CNS, CHRNA3 variation modulates nicotine's effect on prepulse inhibition of startle (PMID:23604333), and zebrafish chrna3 knockout alters alcohol self-administration and tolerance through changes in cholinergic, glutamatergic, and GABAergic signaling (PMID:40992927).

1. 1998 Medium

   Defining the genomic architecture of the CHRNA3/A5/B4 cluster on 15q24 provided the structural framework needed to pursue mutational and regulatory analyses of the α3 subunit gene.

   Evidence Genomic cloning and structural characterization of CHRNA3 gene organization and chromosomal mapping

   PMID:9921897

   Open questions at the time

   • No functional data on receptor assembly or stoichiometry
   • Promoter regulatory elements not yet tested
2. 2001 High

   Knockout of the mouse α3 subunit established that CHRNA3 is required for fast nicotinic synaptic transmission in autonomic ganglia, explaining the severe autonomic phenotype (megacystis, pupil dilation, perinatal death).

   Evidence Chrna3 knockout mice with bladder contraction pharmacological assays showing absent nicotine response

   PMID:11450844

   Open questions at the time

   • Human disease causation not yet demonstrated
   • Contribution to CNS function not addressed
   • Whether other nAChR subunits can partially compensate in specific ganglia unknown
3. 2010 Medium

   CHRNA3 rs1051730 was linked to reduced prepulse inhibition in two independent human cohorts, revealing a CNS function for CHRNA3 in sensorimotor gating beyond its autonomic role.

   Evidence Genetic association of rs1051730 with PPI of acoustic startle in healthy volunteers and schizophrenia patients

   PMID:20393456

   Open questions at the time

   • Association does not prove causality at CHRNA3 vs linked variants
   • Neural circuit mediating the PPI effect not identified
   • No pharmacological confirmation yet
4. 2011 Medium

   Promoter haplotype testing showed CHRNA3 promoter variants themselves do not strongly drive allelic expression imbalance in brain, redirecting attention to distal regulatory elements.

   Evidence Luciferase reporter assays in BE(2)-C cells and allelic expression imbalance analysis in post-mortem brain tissue

   PMID:21858091

   Open questions at the time

   • Distal enhancer elements not yet tested
   • Tissue-specific regulation beyond brain not examined
5. 2012 Medium

   The rs6495309 polymorphism in the CHRNA3 promoter region was shown to alter transcriptional activity in response to nicotine and tobacco chemicals in an allele-dependent manner, linking environmental exposure to genotype-specific gene regulation.

   Evidence Luciferase reporter assays with nicotine/tobacco chemical treatments in lung cancer cell lines

   PMID:23056235

   Open questions at the time

   • In vivo relevance of ligand-dependent promoter modulation not confirmed
   • Transcription factors mediating the response not identified
6. 2013 Medium

   Two advances refined CHRNA3 regulation and CNS pharmacology: intergenic SNPs rs8023462/rs6495309 were shown to recruit allele-specific nuclear proteins including GATA factors to regulate CHRNA3/B4 expression, and a pharmacological challenge study demonstrated that CHRNA3 genotype determines whether nicotine enhances or worsens sensorimotor gating.

   Evidence EMSA and luciferase assays identifying GATA binding at rs8023462; double-blind placebo-controlled nicotine crossover study with PPI and rs1051730 genotyping

   PMID:23604333 PMID:23872218

   Open questions at the time

   • GATA factor identity not specified beyond family level
   • Whether PPI genotype effect is mediated by CHRNA3 expression level or receptor function unknown
   • ChIP confirmation of GATA binding at endogenous locus not performed
7. 2016 Medium

   GTEx eQTL analysis revealed that a shared enhancer haplotype (tagged by rs880395) increases both CHRNA3 and CHRNA5 expression, while brain-region-specific regulation of CHRNA3 maps to a distinct CHRNB4 3'UTR haplotype, indicating multi-layered cis-regulatory control.

   Evidence eQTL analysis across GTEx tissues with linkage disequilibrium and chromatin looping inference

   PMID:27758088

   Open questions at the time

   • Physical chromatin contact not directly demonstrated (inferred from eQTL data)
   • Mechanism of region-specific regulation not elucidated
8. 2021 High

   Identification of biallelic CHRNA3 loss-of-function variants in two unrelated families with panautonomic failure proved that CHRNA3 is essential for human autonomic ganglionic transmission, translating the mouse knockout phenotype to a defined Mendelian disease.

   Evidence Whole exome sequencing, co-segregation in two families, structural modeling of p.D230N at pentameric subunit interface

   PMID:33947782

   Open questions at the time

   • No electrophysiological recording from patient ganglia
   • Receptor assembly and trafficking effects of mutations not tested in vitro
   • Potential CNS manifestations not systematically assessed
9. 2025 High

   Three studies broadened the functional portrait: zebrafish chrna3 knockout established a role in alcohol tolerance via cholinergic/glutamatergic/GABAergic signaling; transgenic reporters mapped chrna3 expression to enteric, lateral line, and spinal motor/interneuron populations; and chromosome conformation capture identified rs2036527 as a functional cis-regulatory variant in a FOXA2-bound enhancer that physically contacts the CHRNA3 promoter.

   Evidence Zebrafish KO with behavioral and transcriptomic analysis; transgenic fluorescent reporters with cell-type markers; 3C, ChIP, luciferase, and allele-specific expression in human lung tissue

   PMID:39686588 PMID:40755048 PMID:40992927

   Open questions at the time

   • Whether FOXA2-enhancer mechanism operates in neuronal tissues beyond lung not tested
   • Circuit-level mechanism by which chrna3 loss alters alcohol response unknown
   • Human in vivo confirmation of enhancer-promoter loop pending

• Key unresolved questions include the structural basis for α3 subunit incorporation into specific pentameric receptor subtypes, the identity of CHRNA3-containing receptor complexes in different CNS circuits, and whether enhancer-mediated regulation by FOXA2 and GATA factors operates in autonomic ganglia where CHRNA3 function is most critical.
• No cryo-EM or crystallographic structure of α3-containing pentamers
• Subunit stoichiometry preferences (α3β4 vs α3β2 vs mixed) in native tissue not resolved
• Tissue-specific enhancer activity in autonomic neurons not tested